A PHASE-II TRIAL OF DIAZIQUONE (AZQ) IN MIXED MESODERMAL SARCOMAS OF THE UTERUS - A GYNECOLOGIC ONCOLOGY GROUP-STUDY

被引：0
|
作者：
SLAYTON, RE
BLESSING, JA
CLARKEPEARSON, D
机构：
[1] RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT MED,MED ONCOL SECT,CHICAGO,IL 60612
[2] ROSWELL PK CANC INST,GYNECOL ONCOL GRP,BUFFALO,NY
[3] DUKE UNIV,MED CTR,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL,DURHAM,NC 27710
来源：
INVESTIGATIONAL NEW DRUGS | 1991年 / 9卷 / 01期
关键词：
DIAZIQUONE; MIXED MESODERMAL SARCOMA; UTERUS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AZQ was given intravenously to 23 patients with mixed mesodermal sarcoma of the uterus refractory to conventional treatment at a dose of 22.5-30 mg/m2 q three weeks. There was one partial response lasting seven weeks and one drug-related death. Based upon the activity observed in this trial, there does not appear to be a significant role for AZQ as a salvage agent for mixed mesodermal sarcomas of the uterus at the dose and schedule tested.
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
12345